DC
ELDN icon

Derby & Company’s Eledon Pharmaceuticals ELDN Stock Holding History

Derby & Company’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,641
Closed -$207K – 30
2018
Q2 		$207K Hold
1,641
– – 0.13% 36
2018
Q1 		$149K Buy
1,641
+617
+60% +$45.4K 0.1% 38
2017
Q4 		$75K Buy
+1,024
New +$77.3K 0.05% 47

Other funds holding ELDN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAMU
Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

Derby & Company's ELDN Position: Q3 2018 in Review

Derby & Company sold out of Eledon Pharmaceuticals (ELDN) in Q3 2018, closing a stake of 1,641 shares — an estimated $207K sold.

Derby & Company first reported a position in ELDN in Q4 2017 and held it in 3 quarters. The position peaked at $207K in Q2 2018. 20 funds tracked by Wall St. Rank hold ELDN as of Q3 2018.

  • Derby & Company reported no remaining Eledon Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Derby & Company sold 1,641 Eledon Pharmaceuticals shares in Q3 2018, an estimated $207K.
  • Derby & Company first reported a position in Eledon Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Derby & Company's Eledon Pharmaceuticals position peaked at $207K in Q2 2018.
  • 20 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2018.

Based on Derby & Company's 13F filing for Q3 2018, filed 14 Nov 2018.